Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.
about
Design and Prototype of an Automated Column-Switching HPLC System for Radiometabolite AnalysisTactics for preclinical validation of receptor-binding radiotracers.New methodologies for the preparation of carbon-11 labeled radiopharmaceuticals.11C-Labeling of Aryl Ketones as Candidate Histamine Subtype-3 Receptor PET Radioligands through Pd(0)-Mediated 11C-Carbonylative Coupling.Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.Translocator protein ligands based on N-methyl-(quinolin-4-yl)oxypropanamides with properties suitable for PET radioligand development.Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[11C]methoxyphenyl) quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2.[Carboxyl-11 C]Labelling of Four High-Affinity cPLA2α Inhibitors and Their Evaluation as Radioligands in Mice by Positron Emission Tomography."In-loop" [11 C]CO2 fixation: Prototype and proof of concept.[11 C]Fluoroform, a Breakthrough for Versatile Labeling of PET Radiotracer Trifluoromethyl Groups in High Molar Activity.Small-molecule PET Tracers for Imaging Proteinopathies.In Vitro and in Vivo Evaluation of 11C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies.Quinuclidine and DABCO Enhance the Radiofluorinations of 5-Substituted 2-Halopyridines.Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice.AlF-NODA Benzothiazole Derivatives as Imaging Agents for Cerebrovascular Amyloid in Cerebral Amyloid AngiopathyEmerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
P2860
Q37290845-4B8FE1D1-E230-4CFE-A895-AD68BCA73D9CQ38984519-3F528C1A-9686-4DED-9441-8C5F97F1E459Q39361125-9272F0E9-B61B-4C49-ABF5-920C20ABE163Q41148398-0B4325EE-46B6-459D-AAD9-55B7320C40FCQ44347551-B9542F2E-FE85-447B-BD84-6D027BBC4C0DQ46087990-473F61E6-C635-4541-9192-5A70255DF017Q46771818-AF5DF2D1-3CE8-44B1-87AC-38704F45F7CEQ47565244-E3E770DD-47C6-41EE-A365-6CA300D982A8Q47697824-6DA1284C-B679-4939-99A9-1E76A31300B1Q47720226-C92C372D-130A-4F51-8A2F-7BFD5630C979Q47926474-54502C9D-5AB3-4DEB-AD77-3601D5971FF8Q52315796-EC9E5261-FFEA-4C6D-8A45-12ACCAEC4F97Q53705296-83C05884-E955-4B18-82D9-331EC7D61D22Q55385817-E8E3D5F4-8C9A-4932-A74E-5797CDD1C6D5Q58581176-5CE59B63-3901-4A90-97FE-2DF32143C47CQ58751451-D45BFC70-0EA4-4C1A-8453-0A18223D9934
P2860
Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Considerations in the Developm ...... adioligands for Brain Imaging.
@en
type
label
Considerations in the Developm ...... adioligands for Brain Imaging.
@en
prefLabel
Considerations in the Developm ...... adioligands for Brain Imaging.
@en
P2860
P1476
Considerations in the Developm ...... adioligands for Brain Imaging.
@en
P2093
Victor W Pike
P2860
P304
P356
10.2174/0929867323666160418114826
P577
2016-04-18T00:00:00Z